Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nothing earth shattering but enough to make good money buying at .06 per share right now. Maybe .30-.50 per share no change in float
seems to be moving up today. I'm banking on a Cronos buyout
$0.0647 +0.0059 (+10.03%)
Bid x Size $0.0667 x 50,000 Ask x Size $0.0675 x 97,100
again, pps is down but no real volume. I predict share price over .10 by the end of February and that would be a nice 40-50% gain!
No one is selling any large blocks down here. Have to hit the ask to buy more than a few thousand shares
CRON is a likely buyer. May not be an earth shattering deal but VVCIF & CRON have similar revenues and CRON has a nice cash position. The recent VVCIF hires may have something to do with getting a deal done IMO.
Does anyone know how it is possible to purchase shares @ .000001? A few trades were processed for 10,000,000 shares @ .000005, many more at lower volume. I see multiple trades for 10 mil shares and that means the purchase price was $10. If these shares sell @ .0001 the trader will have $990 in gains every time. I could see this happening at least a few hundred times over a year and that translates to some big/easy money.
Any doubts in RNVA check out what PHIL did this year. Very similar situation here.
I’ll be the first to admit I was wrong about where I saw the market value going for cgen. It appears that the horse is very strong with great lineage but it’s being ridden by a sub par jockey.
I have a buddy that sold PHIL at .0001 after buying at .0001. It ran to .015. He’s share would’ve been around 500k if he held for .01. You don’t buy .0001’s to sell at .0001. That’s not the game.
Does anyone have a clue what is happening here?
"subject to the Board of Directors’ discretion to abandon such amendment" If this thing has legs they will let it run.
Christopher Diamantis, see filing below.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 30, 2020
Rennova Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-35141 68-0370244
(Commission File Number) (I.R.S. Employer Identification No.)
931 Village Boulevard, Suite 905, West Palm Beach,
Florida 33409
(Address of Principal Executive Offices) (Zip Code)
(561) 855-1626
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
None None None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 1.01. Entry into a Material Definitive Agreement.
On June 30, 2020, Rennova Health, Inc. (the “Company”) entered into an Exchange Agreement (the “Agreement”) with Christopher Diamantis, who had previously been a director of the Company until his resignation on February 26, 2020. Pursuant to the Agreement, the Company issued to Mr. Diamantis 22,000 shares of its Series M Convertible Preferred Stock (the “Preferred Stock”) in exchange for the extinguishment of the Company’s indebtedness to Mr. Diamantis totalling $18,849,637.06, including accrued interest, as of June 30, 2020.
The terms of the Preferred Stock were set forth in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 16, 2020. In particular, each holder of the Preferred Stock shall be entitled to vote on all matters submitted to a vote of the holders of the Company’s common stock. Regardless of the number of shares of Preferred Stock outstanding and so long as at least one share of Preferred Stock is outstanding, the outstanding shares of Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. Each outstanding share of the Preferred Stock shall represent its proportionate share of the 51% allocated to the outstanding shares of Preferred Stock in the aggregate. The Preferred Stock shall vote with the common stock and any other voting securities as if they were a single class of securities.
The foregoing description of the Agreement does not purport to be complete and is qualified by reference to the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 3.02. Unregistered Sales of Equity Securities.
The information set forth in Item 1.01 is incorporated herein by reference.
Item 3.03. Material Modification to Rights of Security Holders.
The information set forth in Item 1.01 is incorporated herein by reference.
Item 5.01. Changes in Control of Registrant.
The information set forth in Item 1.01 is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Exhibit Description
10.1 Exchange Agreement, dated as of June 30, 2020, between Rennova Health, Inc. and Christopher Diamantis
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 8, 2020 RENNOVA HEALTH, INC.
By: /s/ Seamus Lagan
Seamus Lagan
Chief Executive Officer
(principal executive officer)
3
The company's largest shareholder has forgiven roughly 20 million in debt for controlling interest and is now the largest shareholder of RNVA. Don't you think he will want to recoup his 20 million nd then some? No one forgives 20 million without a way to get it back unless it's the morons in Washington DC. Just food for thought.
It's a bottom basement penny stock. No one should be surprised. The majority shareholder has forgiven almost 20 million in personal loans for control of the stock/company. Frankly, no one cares what is going on with this company. Just play the PR game and hope momentum takes us to penny land. My favorite play this year was PHIL. Traded at .0001 and shot up to .015 on nothing but a bunch of promises. It still trades at .005. Everyone here would kiss each other's A$$ if that happens here.
On June 30, 2020, Rennova Health, Inc. (the “Company”) entered into an Exchange Agreement (the “Agreement”) with Christopher Diamantis, who had previously been a director of the Company until his resignation on February 26, 2020. Pursuant to the Agreement, the Company issued to Mr. Diamantis 22,000 shares of its Series M Convertible Preferred Stock (the “Preferred Stock”) in exchange for the extinguishment of the Company’s indebtedness to Mr. Diamantis totalling $18,849,637.06, including accrued interest, as of June 30, 2020.
The terms of the Preferred Stock were set forth in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 16, 2020. In particular, each holder of the Preferred Stock shall be entitled to vote on all matters submitted to a vote of the holders of the Company’s common stock. Regardless of the number of shares of Preferred Stock outstanding and so long as at least one share of Preferred Stock is outstanding, the outstanding shares of Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. Each outstanding share of the Preferred Stock shall represent its proportionate share of the 51% allocated to the outstanding shares of Preferred Stock in the aggregate. The Preferred Stock shall vote with the common stock and any other voting securities as if they were a single class of securities.
The foregoing description of the Agreement does not purport to be complete and is qualified by reference to the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Christopher Diamantis is negotiating for a controlling share of Rennova's capital stock. In exchange, he would cancel the $22.3 million the company owes him from previous loans.
Why would this guy get involved is the million-dollar question?
Guess I wasn't wrong yesterday when I said .0002's were coming. no apologies necessary. xoxo
Understood. I'm sure everyone would like to see some news hit to speed up the process. All signs are pointing toward that soon!
Ask x Size $0.0001 x 21,770,464
I agree that even if .0002 paints today that there is 99% chance of more .0001's coming back tomorrow.
Still only $2177 in the way for now.
Ask x Size $0.0001 x 44,122,471
$4,413 to move up to .0002?!!!
Looking at todays trades and there are an awful lot of trades posted as question marks as opposed to buy or sells. Anyone know what the ? could represent?
TY is advance.
I feel like the pps settles @ $7-$9 until late 3rd early 4th Q. Then we see $5 or $40. Please be $40.
Per my boy Wang, “I figured why cgen has gotten smacked in the last week. So ark funds. The cathie wood fund that started this whole craze owns 29% of cgen. They had record outflows this week so they were forced to sell some stock. Ark was the firm that bought tesla when it was $100 and said it was going to $2000. They also own a huge chunk of BIDU. Stock fell from 350 to 280 this past week (similar selling to cgen)”
“Ark still owns a ton of cgen in all their different funds. Everything they invest in is next generation technology.”
My gut says CRON buys them. They have piles of money and same revenue. No brainer.
Agreed. Doesn’t help to complain about the past. Truth is the company is undervalued but current so called leadership/management is a disaster. They remind me of the Teldar Paper executives in the movie Wall Street aka “Greed is Good” scene.
Barry and his team are a disaster. They allowed Daniel Laflamme to destroy this company and proudly displayed him as a leader of the company. This company needs to be sold.
Yeah prob a little harsh it did run up when it was aligned with the infamous NTEK (scam of the decade).
This company owns some rights to the worst movies ever produced. The best retail placement they’ve ever had was in big tubs previously used to haul watermelons near the check out aisle at select Walmarts. For over a decade this stock has been priced at .01.
My advice is to invest in yourself before you invest in this company.
The new rating couldn’t have been timed worse. Jefferies and it’s analyst look foolish
Reorganization and job cuts inevitable after canceling the offering to raise capital.
New Analyst Rating---Jeffries puts a $25 target and buyout of CGEN imminent
Compugen assumed with a Buy at Jefferies Jefferies analyst Chris Howerton assumed coverage of Compugen with a Buy rating with a price target of $25, up from the firm's previous target of $20. The company's lead assets, alphaPVRIG and alphaTIGIT, are novel anti-cancer/immune-checkpoint drugs with evidence that supports pathways for broad tumor types, suggesting each drug could become "Keytruda-like," Howerton tells investors.
Read more at:
https://thefly.com/n.php?id=3174816
Recovered nicely from Trump Covid market reaction. Looking forward to positive test results any day now!
This company has no clue. Great spenders of your money. Awful to its retail investors. Bait and switch and line their own pockets.
"Compugen’s (CGEN) early-stage study is evaluating the safety, tolerability and preliminary antitumor activity of COM701 (the company’s first-in-class anti-PVRIG antibody) in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) and BMS-986207."
https://finance.yahoo.com/news/compugen-starts-dosing-early-stage-053529308.html
I can see CGEN at $60-$75 per share min next year if a buyout occurs. I know a lot of heavy hitters are watching this and a working partnership with Bristol Myers Squibb, a 140 billion dollar beast is very encouraging.
No other choice right now unfortunately.
All I have to say is wow!! This could really be a life changer. I really believe this could be a $60-80 stock in a year.
Getting this CHART moving upwards is all I want to see!
One major variable will be the 100 million in cash they are trying to raise in the next 2 years. If they avg. .30 per new share they will add 333,333,333 new shares to the O/S more than doubling the current count.
VIVO Cannabis™ Announces Filing of Preliminary Base Shelf Prospectus
https://www.vivocannabis.com/press-releases/vivo-cannabis-announces-filing-of-preliminary-base-shelf-prospectus/
Wall Street rumors scaring some weak hands. CGEN could bounce really fast with next patient test results. CGEN also being courted for a buyout by this time next year.